Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12B97 | ISIN: NL0010872495 | Ticker-Symbol: 0PQ
Tradegate
14.11.24
17:52 Uhr
3,738 Euro
-0,036
-0,95 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PROQR THERAPEUTICS NV Chart 1 Jahr
5-Tage-Chart
PROQR THERAPEUTICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
3,7523,82219:28
3,7523,82019:28

Aktuelle News zur PROQR THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.11.ProQR Therapeutics N.V. - 6-K, Report of foreign issuer-
03.11.ProQR Therapeutics Aktie: Weg in die Zukunft geebnet!431ProQR Therapeutics, ein niederländisches Biotechnologieunternehmen, zeigt sich trotz herausfordernder Marktbedingungen widerstandsfähig. Die Aktie verzeichnete am 2. November 2024 einen leichten Rückgang...
► Artikel lesen
29.10.ProQR Therapeutics (NASDAQ:PRQR) Upgraded to Strong-Buy at Raymond James1
25.10.ProQR Therapeutics N.V.: ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement1
25.10.ProQR Therapeutics N.V. - 6-K, Report of foreign issuer2
23.10.ProQR Therapeutics prices $75M offering and enters $12M private placement4
23.10.ProQR Therapeutics N.V.: ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement74LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) ("ProQR"), a company dedicated to changing lives through transformative RNA therapies...
► Artikel lesen
22.10.ProQR Therapeutics N.V.: ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares2
PROQR THERAPEUTICS Aktie jetzt für 0€ handeln
07.10.ProQR Therapeutics N.V.: ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society4
30.09.ProQR Therapeutics files for $300M mixed securities shelf1
30.09.ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase2
10.09.ProQR Therapeutics N.V.: ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference1
08.08.ProQR Therapeutics N.V. - 6-K, Report of foreign issuer2
08.08.ProQR Therapeutics N.V.: ProQR Announces Second Quarter 2024 Operating and Financial Results101AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and...
► Artikel lesen
22.05.ProQR Therapeutics N.V. - 6-K, Report of foreign issuer1
09.05.ProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial Results406Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting - Management to host webinar today at 8:00 am EDT to highlight...
► Artikel lesen
13.03.ProQR Therapeutics N.V.: ProQR Announces Year End 2023 Operating and Financial Results1.001Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further...
► Artikel lesen
19.01.ProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024611Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation...
► Artikel lesen
05.01.ProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration528Partnership focused on utilizing Axiomer to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR's commitment to advance the...
► Artikel lesen
08.12.23ProQR Therapeutics N.V.: ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets507Divestment of sepofarsen and ultevursen completed - Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome Agreement provides ProQR with initial payment...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1